Dolores Ochoa Mazarro-rekin lankidetzan egindako argitalpenak (5)

2024

  1. Use of Exposure Data to Establish Causality in Drug–Adverse Event Relationships: An Example with Desvenlafaxine

    Pharmaceuticals, Vol. 17, Núm. 1

2023

  1. Genetic Variation in CYP2D6 and SLC22A1 Affects Amlodipine Pharmacokinetics and Safety

    Pharmaceutics, Vol. 15, Núm. 2

  2. Impact of polymorphisms in CYP and UGT enzymes and ABC and SLCO1B1 transporters on the pharmacokinetics and safety of desvenlafaxine

    Frontiers in Pharmacology, Vol. 14

2022

  1. Association between CYP2C19 and CYP2B6 phenotypes and the pharmacokinetics and safety of diazepam

    Biomedicine and Pharmacotherapy, Vol. 155

  2. Polymorphism of Drug Transporters, Rather Than Metabolizing Enzymes, Conditions the Pharmacokinetics of Rasagiline

    Pharmaceutics, Vol. 14, Núm. 10